Share price of this small-cap pharma stock jumped by nearly 4.75% on BSE to Rs. 5,300 in the morning trading session of March 27th, from its previous close of Rs. 5,059.55, after the company announced receiving approval.
With a market capitalisation of Rs. 13,094.5 crores, at 12:34 p.m. the shares of AstraZeneca Pharma India Limited were trading in the green at Rs. 5,231.9, up by nearly 2.94 percent.
In the last one year, the company has delivered positive returns of about 56.7 percent and nearly 18.2 percent in the last six months. However, so far in 2024, it has delivered negative returns of around 7.3 percent.
According to recent regulatory filings with the stock exchanges, AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg (Enhertu) for its sale and distribution.
Trastuzumab deruxtecan is for the treatment of adult patients with unresectable or metastatic HER2-Low breast cancer who have previously received metastatic chemotherapy or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Additionally, it is also recommended for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously undergone a trastuzumab-based regimen.
In terms of financials, the company’s revenue from operations grew by nearly 22.4 percent YoY from Rs. 250 crore in Q3 FY22-23 to Rs. 306 crore in Q3 FY23-24.
However, the net profit of the company decreased by 44.8 percent YoY, from Rs. 29 crore in Q3 FY22-23 to Rs. 16 crore in Q3 FY23-24.
As of December 2023, FIIs hold 2.66 percent of the shares, whereas DIIs hold 2.76 percent of the shares in the company, aggregating to 5.42 percent of the institutional holdings.
AstraZeneca Pharma India Limited is a pharmaceutical company and is involved in the business of manufacture, distribution and marketing of pharmaceutical products.
Established in 1979, the company largely focuses on the discovery, development and commercialisation of prescription medicines, which are generally used to treat diseases in therapy areas such as Oncology, Biopharmaceuticals and Rare Diseases.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
